Study design
In this randomized prospective study were included patients that were
submitted to Spatz3® (Genco et al.,
2013)[2] (Spatz ABS—Spatz FGIA, Inc., Jericho,
NY, USA).
adjustable IGB treatment between October 2016 and June 2018 in a private
clinic (EndogastroRio) in Rio de Janeiro/Brazil.